|
|
Vaccine Detail
|
Dendritic Cell-gp100-MART-1 Antigen Vaccine |
| Vaccine Information |
- Vaccine Name: Dendritic Cell-gp100-MART-1 Antigen Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007371
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MLANA, gp100
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: An autologous dendritic cells vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 (melanoma antigen recognized by T-cells) antigen; both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells. (NCIT_C2214).
|
| Host Response |
|
|
| References |
NCIT_C2214: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2214]
|
|
